| Therapeutic | Inotuzumab |
| Target | CD22 |
| Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYRFTNYWIHWVRQAPGQGLEWIGGINPGNNYATYRRKFQGRVTMTADTSTSTVYMELSSLRSEDTAVYYCTREGYGNYGAWFAYWGQGTLVTVSS |
| Light Chain | DVQVTQSPSSLSASVGDRVTITCRSSQSLANSYGNTFLSWYLHKPGKAPQLLIYGISNRFSGVPDRFSGSGSGTDFTLTISSLQPEDFATYYCLQGTHQPYTFGQGTKVEIK |
| 100% seqID Fv Structure | None |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
| Format | Whole mAb ADC |
| Isotype | G4 |
| Highest Clinical Trial (August '23) | Approved |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2004 |
| INN Year Recommended | 2005 |
| Companies Involved | Alliance for Clinical Trials in Oncology%3BCancer Research UK%3BCase Comprehensive Cancer Center%3BChildren%27s Oncology Group%3BErasmus MC%3BM. D. Anderson Cancer Center%3BNational Cancer Institute %28USA%29%3BPfizer%3BSWOG%3BUniversity College London%3BUniversity of Texas M. D. Anderson Cancer Center%3BCelltech Group |
| Conditions Approved | Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Active | Precursor B-cell lymphoblastic leukaemia-lymphoma%3BChronic myeloid leukaemia |
| Conditions Discontinued | Acute biphenotypic leukaemia%3BBurkitt%27s lymphoma%3BDiffuse large B cell lymphoma%3BNon-Hodgkin%27s lymphoma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
